CryoLife, Inc. (NYSE:CRY) CAO Amy Horton sold 4,000 shares of the business’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $19.00, for a total value of $76,000.00. Following the sale, the chief accounting officer now owns 98,705 shares in the company, valued at approximately $1,875,395. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Shares of CryoLife, Inc. (CRY) traded down $0.20 on Monday, hitting $18.65. The stock had a trading volume of 114,300 shares, compared to its average volume of 164,817. The firm has a market cap of $623.98, a P/E ratio of 45.49 and a beta of 0.82. CryoLife, Inc. has a one year low of $14.02 and a one year high of $24.00. The company has a quick ratio of 4.90, a current ratio of 5.96 and a debt-to-equity ratio of 0.29.

CryoLife (NYSE:CRY) last issued its earnings results on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.08. The company had revenue of $44.00 million for the quarter, compared to the consensus estimate of $44.60 million. CryoLife had a return on equity of 6.43% and a net margin of 5.28%. The firm’s quarterly revenue was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.13 EPS. equities analysts predict that CryoLife, Inc. will post 0.28 earnings per share for the current year.

WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/11/13/amy-horton-sells-4000-shares-of-cryolife-inc-cry-stock.html.

CRY has been the topic of several recent analyst reports. Lake Street Capital boosted their price objective on CryoLife to $26.00 and gave the stock a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research downgraded CryoLife from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. BidaskClub downgraded CryoLife from a “buy” rating to a “hold” rating in a report on Monday, July 24th. TheStreet downgraded CryoLife from a “b” rating to a “c+” rating in a report on Monday, October 30th. Finally, Canaccord Genuity restated a “buy” rating and set a $25.00 price objective on shares of CryoLife in a report on Monday, October 9th. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $23.63.

Institutional investors and hedge funds have recently modified their holdings of the company. Municipal Employees Retirement System of Michigan increased its holdings in shares of CryoLife by 3.2% in the 1st quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock valued at $102,000 after purchasing an additional 190 shares during the period. State of Alaska Department of Revenue increased its holdings in shares of CryoLife by 80.8% in the 2nd quarter. State of Alaska Department of Revenue now owns 5,387 shares of the medical equipment provider’s stock valued at $107,000 after purchasing an additional 2,407 shares during the period. First Mercantile Trust Co. increased its holdings in shares of CryoLife by 5.6% in the 2nd quarter. First Mercantile Trust Co. now owns 5,448 shares of the medical equipment provider’s stock valued at $109,000 after purchasing an additional 291 shares during the period. Creative Planning increased its holdings in shares of CryoLife by 3.0% in the 2nd quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock valued at $136,000 after purchasing an additional 200 shares during the period. Finally, Victory Capital Management Inc. increased its holdings in shares of CryoLife by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 6,937 shares of the medical equipment provider’s stock valued at $138,000 after purchasing an additional 1,041 shares during the period. Institutional investors own 70.34% of the company’s stock.

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Insider Buying and Selling by Quarter for CryoLife (NYSE:CRY)

Receive News & Stock Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related stocks with our FREE daily email newsletter.